Original Article

THAM Administration to Pediatric Trauma Patients in a Combat Zone

Authors: Jason F. Naylor, DSc, PA-C, Michael D. April, MD, PhD, Guyon J. Hill, MD, Kelley M. Kempski, , Allyson A. Arana, PhD, Steven G. Schauer, DO, MS

Abstract

Objectives: Pediatric casualties made up a significant proportion of patients during the recent military conflicts in Iraq and Afghanistan. Damage control resuscitation strategies used by military physicians included rapid reversal of metabolic acidosis to mitigate its pathophysiologic consequences, primarily through hemorrhage control and volume restoration. Alkalizing agents, including tris(hydroxymethyl)aminomethane (THAM), are potential therapeutic adjuncts to treat significant acidosis. There is, however, limited published data on THAM administration in the pediatric trauma population. We compared demographics and outcomes among pediatric trauma patients in Afghanistan and Iraq receiving THAM versus those not receiving THAM.

Methods: We queried the Department of Defense Trauma Registry for all of the pediatric patients admitted to US and Coalition fixed-facility hospitals in Afghanistan and Iraq from January 2007 to January 2016. We retrieved data on age, sex, location, mechanism of injury, Injury Severity Scores, ventilator days, days in the intensive care unit, days of total hospitalization, and survival to hospital discharge. We excluded subjects if they were dead on arrival to the emergency department.

Results: From January 2007 to January 2016, there were 3386 pediatric subjects that met our inclusion criteria. Of these, 15 received THAM. The youngest subject receiving THAM was a 2-month-old burn victim. Subjects receiving THAM were more likely to be injured by submersion or burn (P < 0.001), had higher composite Injury Severity Scores (17 vs 10; P < 0.001) and Abbreviated Injury Scores for the thorax and abdomen (P = 0.004 and P = 0.019, respectively), and longer ventilator days/intensive care unit stays/hospital lengths of stay (P < 0.001/P < 0.001/P = 0.013). In addition, subjects receiving THAM had a lower survival rate than subjects not receiving THAM (73.3% vs 91.7%; P = 0.011).

Conclusions: THAM was administered rarely to pediatric trauma casualties during the conflicts in Afghanistan and Iraq. Subjects receiving THAM were more critically injured than the baseline population.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Moore EE, Thomas G. Orr Memorial Lecture. Staged laparotomy for the hypothermia, acidosis, and coagulopathy syndrome. Am J Surg 1996;172:405-410.
 
2. Lier H, Krep H, Schroeder S, et al. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 2008;65:951-960.
 
3. Martini WZ, Pusateri AE, Uscilowicz JM, et al. Independent contributions of hypothermia and acidosis to coagulopathy in swine. J Trauma 2005;58:1002-1010.
 
4. Kimmoun A, Ducrocq N, Sennoun N, et al. Efficient extra- and intracellular alkalinization improves cardiovascular functions in severe lactic acidosis induced by hemorrhagic shock. Anesthesiology 2014;120:926-934.
 
5. Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007;62:307-310.
 
6. Jansen JO, Thomas R, Loudon MA, Brooks A. Damage control resuscitation for patients with major trauma. BMJ 2009;338:b1778.
 
7. Kraut JA, Madias NE. Lactic acidosis: current treatments and future directions. Am J Kidney Dis 2016;68:473-482.
 
8. Wiederkehr M, Emmett M. Bicarbonate therapy in lactic acidosis. UpToDate. 2017.
 
9. Sabatini S, Kurtzman NA. Bicarbonate therapy in severe metabolic acidosis. J Am Soc Nephrol 2009;20:692-695.
 
10. Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol 2010;6:274-285.
 
11. Morris CG, Low J. Metabolic acidosis in the critically ill: part 2. Causes and treatment. Anaesthesia 2008;63:396-411.
 
12. Wiederkehr MR, Moe OW. Core concepts and treatment of metabolic acidosis. In: Mount DB, Singh AK, Sayegh MH, , eds. Core Concepts in the Disorders of Fluid, Electrolytes and Acid-Base Balance. New York:Springer;2013;:235-274.
 
13. Nahas GG, Sutin KM, Fermon C, et al. Guidelines for the treatment of acidaemia with THAM. Drugs 1998;55:191-224.
 
14. Weber T, Tschernich H, Sitzwohl C, et al. Tromethamine buffer modifies the depressant effect of permissive hypercapnia on myocardial contractility in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;162( 4 Pt 1 ):1361-1365.
 
15. Kallet RH, Jasmer RM, Luce JM, Lin LH, Marks JD. The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). Am J Respir Crit Care Med 2000;161( 4 Pt 1 ):1149-1153.
 
16. Holmdahl MH, Wiklund L, Wetterberg T, et al. The place of THAM in the management of acidemia in clinical practice. Acta Anaesthesiol Scand 2000;44:524-527.
 
17. Lim S. Metabolic acidosis. Acta Med Indones 2007;39:145-150.
 
18. Zeiler FA, Teitelbaum J, Gillman LM, et al. THAM for control of ICP. Neurocrit Care 2014;21:332-344.
 
19. Gaab MR, Seegers K, Smedema RJ, et al. A comparative analysis of THAM (Tris-buffer) in traumatic brain oedema. Acta Neurochir Suppl (Wien) 1990;51:320-323.
 
20. Lu C, Leibner E, Wright B. The use of tris-hydroxymethyl aminomethane in the emergency department. Clin Exp Emerg Med 2016;3:264-265.
 
21. Cripps M, Kutcher M, Izenberg R, et al. 248: Aggressive correction of severe acidosis with Tris-hydroxyaminomethane (THAM) in severely injured trauma patients. Crit Care Med 2012;40:1-328.
 
22. Glenn MA, Martin KD, Monzon D, et al. Implementation of a combat casualty trauma registry. J Trauma Nurs 2008;15:181-184.
 
23. Oɼ KM, Littleton-Kearney MT, Bridges E, et al. Evaluating the Joint Theater Trauma Registry as a data source to benchmark casualty care. Mil Med 2012;177:546-552.
 
24. Strauss J. Tris (hydroxymethyl) amino-methane (Tham): a pediatric evaluation. Pediatrics 1968;41:667-689.
 
25. Robinson JB, Smith MP, Gross KR, et al. Battlefield documentation of tactical combat casualty care in Afghanistan. US Army Med Dep J 2016;87-94.